Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTORJ Clin Oncol. 2021 Apr 1;39(10):1139-1149. doi: 10.1200/JCO.20.0…

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, ph…

Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana LinfomiJ Clin Oncol. 2021 Apr 10;39(11):1214-1222. doi: 10.1200/JCO.20.02465. Epub 2021 Feb 12…

Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registryBr J Haematol. 2021 Mar 30. doi: 10.1111/bjh.17392.PMID: 33782950 DOI: 10.1111/bjh.1739…

Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and PregnancyBr J Haematol. 2021 Apr;193(1):52-62. doi: 10.1111/bjh.17103. Ep…

Burkitt Lymphoma International Prognostic IndexJ Clin Oncol. 2021 Apr 1;39(10):1129-1138. doi: 10.1200/JCO.20.03288.PMID: 33502927 DOI: 10.1200/JCO.20.03288 目的バーキットリンパ腫 Burkitt lymphoma (BL)は特有の生物学的性質と臨床経過を持つが…

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialClinical Trial Lancet Haema…